Trial Profile

A first in human clinical trial assessing IDE034

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDE 034 (Primary)
Indications Colorectal cancer; Gynaecological cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

28 Feb 2026 Status changed from planning to recruiting.
28 Feb 2026 According to Biocytogen Pharmaceuticals media release, first patient has been dosed in this trial.
25 Feb 2026 According to an IDEAYA Biosciences media release, dosing of the first patient with IDE034 triggers a $5 million milestone payment from IDEAYA to Biocytogen, pursuant to the Option and License Agreement between the companies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com